The New York Stock Exchange announced on December 16 that it would begin proceedings to delist Vicarious Surgical Inc.’s warrants (ticker RBOT WS). The exchange cited the warrants’ abnormally low selling price as the reason for delisting under Section 802.01D of the Listed Company Manual.
Trading in the warrants was suspended immediately, while the company’s Class A common stock (ticker RBOT) remains listed. The continued listing of the common stock is contingent on Vicarious Surgical regaining compliance with NYSE Section 802.01B by October 10, 2026, a deadline that adds pressure on the company’s financial performance.
Vicarious Surgical has stated it does not intend to appeal the NYSE’s determination, indicating management’s acceptance that the warrants no longer meet listing standards and that the company will focus on maintaining its common‑stock listing.
The company’s Q3 2025 financial results show a modest improvement in cash burn, with a revised full‑year 2025 outlook of approximately $45 million—$5 million better than the prior guidance of $50 million. Operating expenses, R&D, and general & administrative costs all declined from the same period in 2024, reflecting disciplined cost control amid a challenging market environment.
The low trading price of the warrants reflects broader investor sentiment about Vicarious Surgical’s financial health. The company previously received a delisting notice in 2023 for its common stock due to a share price below $1, and the current action underscores ongoing concerns about liquidity and profitability. Despite these challenges, the company’s surgical‑robotics platform has earned FDA Breakthrough Device designation, suggesting that the technology remains a strategic asset.
Market reaction to the announcement was limited to the immediate suspension of warrant trading; there was no reported movement in the common‑stock price. The action signals a tightening of regulatory compliance and may influence investor perception of the company’s overall securities offering.
The delisting reduces liquidity for warrant holders and highlights the company’s need to meet NYSE compliance requirements. Continued scrutiny of the common stock and the October 2026 deadline mean that Vicarious Surgical must maintain financial stability and demonstrate sufficient market value to avoid future delisting risks.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.